Molecular targeted therapy for the treatment of gastric cancer

Table 1 Characteristic of molecular targeted agents for gastric cancer treatment

Agent	Type	Target(s)	Current prospects for gastric cancer therapy
Trastuzumab	Recombinant humanized mAb	HER-2	Approved by FDA
Ramucirumab	Humanized mAb	VEGFR	Approved by FDA
Sorafenib	Tyrosine kinase inhibitor	VEGF, PDGF	Phase II or III clinical trials are ongoing
Marimastat	Inhibitor	MMPs	Phase II or III clinical trials are ongoing
Erlotinib	Tyrosine kinase inhibitor	EGFR	Phase II clinical trials are ongoing
Foretinib	Inhibitor	c-Met, KDR VEGFR2	Clinical trials are ongoing
Bevacizumab	Humanized mAb	VEGF	Individualized treatment [47]
Pertuzumab	Recombinant humanized mAb	HER-2	A Phase III clinical trial is ongoing [23]
Sunitinib	Tyrosine kinase inhibitor	VEGF, PDGF, KIT, FLT-3, RET	Promising [50-52]
Bortezomib	Proteasome inhibitor	NF-κB	Promising [59]
Rilotumumab	Inhibitor	c-Met	Promising [69]
Everolimus	Inhibitor	mTOR	Not satisfactory [75]
Lapatinib	Tyrosine kinase inhibitor	EGFR, HER-2	Satisfactory for a specific population [30, 31]
Gefitinib	Tyrosine kinase inhibitor	EFGR	Limited efficacy [26]
Cetuximab	Humanized mAb	EFGR	Not satisfactory [17]
Panitumumab	Humanized mAb	EFGR	Not satisfactory
Flavopiridol	Semi-synthetic flavonoid inhibitor	CDK	Not satisfactory (Phase II clinical trial failed)
Figitumumab	Humanized mAb	IGFR-IR	Phase I clinical trials are ongoing

Abbreviations: mAb monoclonal antibody, EGF epidermal growth factor, EGFR epidermal growth factor receptor, FDA Food and Drug Administration, MMP matrix metalloproteinase, VEGF vascular endothelial growth factor, PDGF platelet-derived growth factor, RET rearranged during transfection, FLT3 FMS-like tyrosine kinase-3 receptor, CDK cyclin-dependent kinase

ISSN: 1756-9966